Avac Event

True Choice in HIV Prevention Involves More than Product Options: Novel strategies in service delivery

The Choice Agenda and presenters from Brazil, Kenya, and South Africa discussed novel strategies for the delivery of HIV prevention interventions. All HIV prevention products have their “Achilles Heels.” Differentiated service delivery supports reaching a wide range of potential users and can overcome challenges with product attributes. Offering different strategies can also make the interface with health care easier and more community friendly.

Speakers:

  • Ines Dourado, Universidade Federal da Bahia
  • Catherine Verde Hashim, AVAC
  • Catherine Martin, Wits RHI
  • Katrina Ortblad, Fred Hutch
  • Adriano Queiroz, City of São Paulo Municipal Health Secretariat
  • Daniel Were, Jhpiego

Thanks to WHO for providing live simultaneous Ukrainian translation and to PAHO for providing live simultaneous translation in Portuguese and Spanish.

Video Recording and English Audio / Ukrainian Audio / Portuguese Audio / Spanish Audio / Slides / Resources

HIVR4P Highlights, Inclusive Prevention Pipeline, Policy Shaping & More

AVAC’s round-up of resources, updates and insights this week includes highlights from HIVR4P, a new vision for an inclusive prevention pipeline, shaping policy and more!

HIVR4P 2024 conference highlights and recap

The 5th HIV Research for Prevention (R4P) conference was held last week in Lima, Peru. The data and discussions centered on accomplishments in HIV prevention, how far the field remains from reaching targets, understanding how choice works and why it matters, and where the research agenda is headed. As AVAC’s Mitchell Warren told Axios, “lenacapavir is on everybody’s lips here at HIVR4P 2024. That’s probably the second-most popular word this week; I think the most popular word is access.

Read more.

Partners and AVAC launched The People’s Research Agenda (PRA), a global initiative driven by communities and advocates to envision an inclusive HIV prevention pipeline and ensure the voices of those most affected by HIV are integrated into HIV prevention research and development. 

Read the report.

Media Highlights

Shaping policy, centering people

AVAC’s Suraj Madoori Joins Developed Country NGO Delegation (DelDev)

Policy Director, Suraj Madoori is one of four new members to join DevDel, one of the 20 voting delegations to the Board of the Global Fund to fight AIDS, Tuberculosis and Malaria. DevDel plays a critical role in the development and evolution of organizational strategy, the funding model, the work of the Secretariat and policy. 

Read more.

AVAC’s Jessica Salzwedel Talks Community Engagement with National Co-ordinating Centre for Public Engagement

In a mini series on community engagement, the National Co-ordinating Centre for Public Engagement interviewed AVAC’s Jessica Salzwedel, Senior Program Manager of Research Engagement on what centering communities truly means.

Listen now.

Avac Event

An Update on the STI R&D Pipeline and Investments

AVAC and Impact Global Health, previously Policy Cures Research, co-hosted a webinar on the current STI R&D pipeline. This discussion featured leading experts sharing the latest advancements in STI diagnostics and treatments, discussing their potential impact on public health and where investments stand.

Speakers:

  • Mandisa Mdingi, Foundation for Professional Development, South Africa
  • Cécile Ventola, Senior Technical Officer at Impact Global Health
  • Birgitta Gleeson, FIND, Switzerland

Recording / Alison Footman Slides / Mandisa Mdingi Slides / Cécile Ventola Slides / Birgitta Gleeson Slides

From Clinical Trial Efficacy to Public Health Impact: A Plan for Accelerating Access to Injectable Lenacapavir for PrEP

This plan provides a broad view of all the moving parts and identifies actions and actors responsible for ensuring time is not wasted and opportunity not squandered.

Spotlight on MPTs Addressing STIs

This graphic outlines the development journey of multipurpose technologies (MPTs) that guard against STIs, including HIV, while also preventing pregnancy. It tracks the advancement of various potential products through different trial stages, emphasizing their combined protective roles. Excerpted from our Advocates’ Guide to Multipurpose Technologies.

AVAC’s Guide to HIVR4P 2024 in Lima

We are looking ahead to the biennial HIV Research for Prevention 2024 conference  in Lima, Peru next week, 6-10 October. HIVR4P is a space where biomedical HIV prevention research, policy and programs takes center stage. Whether you’ll be in Lima or are following from afar, AVAC will keep you connected!

Read on for information on AVAC sessions, a sortable roadmap, the Advocates’ Corner (open all week) and more!  

Resources

  • Use AVAC’s Prevention Roadmap of conference sessions and satellites to find what interests you the most. You can download it as a sortable spreadsheet or PDF.
  • Advocates’ Corner: If you plan to be in Lima, be sure to join us and our CASPR partners at the Advocates’ Corner to take the conversations and themes deeper. The Advocates’ Corner will be open throughout the conference hosting a program of activities along with materials displays and opportunities for informal networking. Be sure to check the events page for updates on programming.
  • AVAC’s Coverage: From the latest news on injectable lenacapavir, to updates on the development of next generation prevention options, to the complex work of implementing the tools that exist today and all the advocacy needed to get it all done, our email dispatches to the Advocates’ Network keep you informed. Follow events in real time on Twitter at #HIVR4P2024 and Instagram.
  • People’s Research Agenda: During HIVR4P, we’ll be releasing the new People’s Research Agenda, a global initiative driven by communities and advocates to define the most urgent priorities, research questions and recommendations for HIV prevention research. We hope it serves as a guide to what is – and should be – discussed at HIVR4P and beyond.

Satellites and Sessions Featuring AVAC and Partners

Sunday, 6 October

Monday, 7 October

Tuesday, 8 October

Wednesday, 9 October

  • Symposium: Reducing burdens and barriers to expand the use of HIV prevention options, 13:30 – 15:00
    This session will explore the promise, potential and risks of using remote tools, such as telemedicine, virtual tools, apps and self-testing and the impact of other tools used to expand access and uptake of HIV prevention modalities. It will also review approaches to overcome misinformation and mistrust.

Thursday, 10 October

Find these resources, conference highlights and more at AVAC’s dedicated HIVR4P 2024 page. And watch this space for new opportunities to come together and shape what happens next.

Avac Event

HIVR4P 2024

The 5th HIV Research for Prevention (R4P) conference is being held in Lima, Peru from 6 to 10 October. Held every two years, HIVR4P is the only global conference to focused exclusively on biomedical HIV prevention, including AIDS vaccines, microbicides, PrEP, treatment as prevention and other approaches. 

See below for conference highlights, recaps and announcements. 

Conference Highlights and Recaps

Announcements

At A Glance: The MPT R&D Pipeline

This graphic shows the status of products in development. Excerpted from our Advocates’ Guide to Multipurpose Technologies.

Advocates’ Guide to Multipurpose Prevention Technologies (MPTs)

Multipurpose prevention technologies (MPTs) are products designed to simultaneously address more than one sexual and reproductive health concern. This advocates’ guide shows the pipeline of products in development, discusses why MPTs are needed, investment, and what advocates can do to push for MPT development and introduction.

The Future of ARV-Based Prevention and More

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

Click here for a view of all large-scale prevention trials.